HGG-37. UPFRONT TARGETED THERAPY FOR THE TREATMENT OF BRAFV600E-MUTANT PEDIATRIC HIGH-GRADE GLIOMA – A MULTI-INSTITUTIONAL EXPERIENCE

INTRODUCTION: Sustained responses to molecular targeted therapy with BRAF with or without MEK inhibitors have been reported in patients with recurrent BRAFV600E-mutant pediatric high-grade gliomas (pHGG). The role of upfront targeted therapy in this population, however, has not yet been established....

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Tom, Yeo, Kee Kiat, Joshirao, Mrinal, Michaiel, George, Tran, Hung, Dahiya, Sonika, Kachurak, Kara, Friedman, Gregory, Huang, Michael, Wright, Karen, Aguilera, Dolly, MacDonald, Tobey, Chi, Susan, Karajannis, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
High Grade Gliomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168236/
http://dx.doi.org/10.1093/neuonc/noab090.101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168236/
http://dx.doi.org/10.1093/neuonc/noab090.101

Ejemplares similares